Nursing Elites

1. A client who received a prescription for cyclosporine ophthalmic emulsion for dry eyes asks the practical nurse (PN) if it is safe to continue using artificial tears. What information should the PN provide?

• A. Avoid using artificial tears because they decrease the efficacy of cyclosporine.
• B. Discontinue the use of both products if transient blurring occurs after administration.
• C. Allow a 15-minute interval between the administration of cyclosporine and artificial tears.
• D. Discontinue the use of cyclosporine and artificial tears when tear production reaches a normal level.

Correct answer: C

Rationale: The correct answer is to allow a 15-minute interval between the administration of cyclosporine and artificial tears. Cyclosporine, an ophthalmic emulsion that increases tear production, can be used in conjunction with artificial tears as long as the products are administered 15 minutes apart. This interval helps to prevent any potential interactions between the two products and ensures optimal effectiveness of cyclosporine for treating dry eyes.

2. Which action should be taken to assess for analgesic tolerance in a client who is unable to communicate?

• A. Review the client's laboratory values for changes in peak and trough levels of the analgesic
• B. Prolong the interval between analgesic medication doses and monitor the client's vital signs
• C. Observe the client for the presence of pain behaviors before the next analgesic dose is due
• D. Ask family members to report behaviors suggesting that the client's pain has returned

Correct answer: C

Rationale: In clients who are unable to communicate, observing for pain behaviors is crucial in assessing analgesic tolerance. Changes in pain behaviors can indicate if the current analgesic regimen is effective or if tolerance has developed. Therefore, closely observing the client for pain behaviors before the next analgesic dose helps healthcare providers evaluate the client's response to pain management. Reviewing laboratory values may not directly reflect analgesic tolerance. Prolonging the interval between doses and monitoring vital signs may not provide direct information on analgesic tolerance. Relying solely on family members to report pain behaviors may not be as accurate or immediate as observing the client directly.

3. The healthcare provider is evaluating the effectiveness of metaproterenol for how do you know it's been effective?

• A. Increased heart rate and blood pressure
• B. Decreased white blood cell count
• C. Decreased wheezing upon auscultation
• D. Decreased respiratory rate

Correct answer: C

Rationale: The effectiveness of metaproterenol, a bronchodilator, is assessed by a decrease in wheezing upon auscultation. Wheezing indicates airway constriction, and a reduction in wheezing signifies improved airflow and bronchodilation due to the medication's action. Therefore, choices A, B, and D are incorrect as they do not directly relate to the expected outcome of metaproterenol therapy.

4. A practical nurse is caring for a client with chronic obstructive pulmonary disease (COPD) who is receiving theophylline. Which symptom indicates that the client may be experiencing theophylline toxicity?

• A. Bradycardia
• B. Tremors
• C. Constipation
• D. Hypotension

Correct answer: B

Rationale: Tremors are a common symptom of theophylline toxicity. Other symptoms that may indicate theophylline toxicity include nausea, vomiting, and seizures. Bradycardia, constipation, and hypotension are not typically associated with theophylline toxicity. It is important for the nurse to monitor the client closely for these signs of toxicity and report them promptly to the healthcare provider to prevent further complications.

5. A client with chronic kidney disease is prescribed erythropoietin. The nurse should monitor for which potential adverse effect?

• A. Hypertension
• B. Hypotension
• C. Tachycardia
• D. Bradycardia

Correct answer: A

Rationale: Erythropoietin is a medication commonly used to stimulate red blood cell production in individuals with chronic kidney disease. One of the potential adverse effects of erythropoietin therapy is hypertension. The increased production of red blood cells can lead to elevated blood pressure levels. Therefore, monitoring for hypertension is essential to ensure the client's safety and well-being while on this medication. Choices B, C, and D are incorrect because hypotension, tachycardia, and bradycardia are not typically associated with erythropoietin therapy. Hypertension is the primary adverse effect to monitor in this case.

Similar Questions